According to The Fly, a Wall Street analyst has provided a review for the Healthcare company yesterday, but retained the same rating on the stock. Analyst Geoff Meacham from Barclays remains bullish on Valeant Pharm International (VRX).
According to TipRanks.com, Meacham is a 4-star analyst with an average return of 5.5% and a 54.9% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Alexion Pharmaceuticals, and Gritstone Oncology Inc.
Read also: Why OncoSec Medical (ONCS) Stock Crashed Today
Valeant Pharm International has an analyst consensus of Moderate Buy.
Valeant Pharm International’s market cap is currently C$12.42B and has a P/E ratio of –. The company has a Price to Book ratio of 2.72.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
